12.12.2018 CO.DON AG  DE000A1K0227

DGAP-News: CO.DON AG: Delivery of machinery to Leipzig site complete


DGAP-News: CO.DON AG / Key word(s): Expansion
CO.DON AG: Delivery of machinery to Leipzig site complete

12.12.2018 / 11:00
The issuer is solely responsible for the content of this announcement.

CO.DON AG - Delivery of machinery to Leipzig site complete

Berlin / Teltow, 12.12.2018 - Only 11 months after the contract was signed, the clean room technology for the new production site has all been delivered. The components were transported from Bologna to Leipzig over recent weeks and taken to the future production areas, where they were assembled on site.

Once it is completed and following an intensive validation and qualification process, the approximately 300 square metre premises will house one of the world's largest cutting-edge facilities for the production of human cells on an industrial scale. In its initial form, which can be expanded at any time, the facility has an annual capacity of around 4,500 cell transplants.

Ralf Jakobs, CEO of CO.DON AG: "To implement a project of this scale precisely on schedule and on budget requires an experienced team and excellent external partners, to whom we owe great thanks. They made a major contribution to this success and to achieving the targets we set and so have played a key role in CO.DON's future.

In addition to producing our own medicinal product, which is authorised for marketing across the EU, the new facility in Leipzig will also function as a contract manufacturing organisation (CMO), cultivating cells for other companies. This strategy is intend to contribute to covering the ongoing fixed costs and staff expenses of the plant and so achieve economies of scale that will impact the company's own margins, and at the same time give us the opportunity of scaling up the production of our own product.

The aim here is to manufacture cell-based, unfinished products, both for high-volume commercial production and for smaller volumes, e.g. in the field of clinical research. These external orders will be carried out using the material and staff resources of CO.DON AG. Talks with potential customers about such production contracts are already taking place."

CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimal invasive treatment of knee cartilage defects that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in appr. 200 clinics in Germany and more than 14,000 patients have already been treated.

In July 2017 CO.DON received EU-wide marketing authorization for the advanced therapy medicinal product from the European Medicines Agency.

The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de

12.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: CO.DON AG
Warthestraße 21
14513 Teltow
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

End of News DGAP News Service

757049  12.12.2018 


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019e 2020e
Umsatzerlöse1 3,62 4,48 5,09 5,60 5,96 5,65 6,86 0,00
EBITDA1,2 -2,50 -2,27 -2,61 -3,41 -6,73 -7,84 -8,62 0,00
EBITDA-Marge3 -69,06 -50,67 -51,28 -60,89 -112,92 -138,76 -125,66 0,00
EBIT1,4 -2,68 -2,48 -2,86 -3,65 -6,98 -8,56 -9,45 0,00
EBIT-Marge5 -74,03 -55,36 -56,19 -65,18 -117,11 -151,50 -137,76 0,00
Jahresüberschuss1 -2,68 -2,49 -2,87 -3,65 -7,05 -6,27 -12,63 0,00
Netto-Marge6 -74,03 -55,58 -56,39 -65,18 -118,29 -110,97 -184,11 0,00
Cashflow1,7 -1,56 -1,78 -2,97 -3,62 -5,88 -8,14 -9,53 0,00
Ergebnis je Aktie8 -0,24 -0,18 -0.18 -0,21 -0,36 -0,55 -0,44 -0,49
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1K022 1,310 41,75
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -4,35
3,63 - 4,24 -5,244
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 Verschoben
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.08.2020 29.05.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-12,55% -41,07% -29,95% -66,41%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CO.DON AG  ISIN: DE000A1K0227 können Sie bei DGAP abrufen

Biotechnologie , A1K022 , CNWK , XETR:CNWK